Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

Dr. Denduluri offers opinion on whether taselisib might one day become a standard of care based on the outcomes of the SANDPIPER study

Tags: ASCO Conference CoverageBreast

Published: 14 June 2018

Recent Videos: ASCO Conference Coverage

video

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

Dr. McKay, Assistant Professor of Medicine, UCSD, discusses factors she considers in deciding which patients should get an I-O combination ...

video

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

Dr. McKay, Assistant Professor of Medicine, UCSD, discusses the unmet needs for clinical trials addressing non-clear cell renal cell carcinoma

video

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

Dr. McKay, Assistant Professor of Medicine, UCSD, shares the results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel ...

video

Rana McKay, MD, dissects the pros and cons of the virtual format of ASCO20

Dr. McKay, Assistant Professor of Medicine, UCSD, dissects the pros and cons of the virtual format of ASCO20 and some ...

video

Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer

Dr. McKay, Assistant Professor of Medicine, UCSD, elaborates on how the advent of hormonal agents for patients with metastatic prostate ...

video

Rana McKay MD, explains approach to treating 2nd-line RCC patients who have received I-O combination

Dr. McKay, Assistant Professor of Medicine, UCSD, explains approach to treating 2nd-line renal cell carcinoma (RCC) patients who have received ...

video

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

Dr. McKay, Assistant Professor of Medicine, UCSD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study ...

video

Rana McKay, MD, shares the design and outcomes of the Javelin Bladder 100 study

Dr. McKay, Assistant Professor of Medicine, UCSD, shares the design and outcomes of the Javelin Bladder 100 study investigating maintenance ...

video

Robert Coleman, MD, describes experience with virtual ASCO20

Dr. Coleman, Chief Scientific Officer, US Oncology Network, describes experience with virtual ASCO20

video

Joyce Liu, MD, describes experience with virtual ASCO20

Dr. Liu, Assistant Professor of Medicine, Dana-Farber Cancer Institute, describes experience with virtual ASCO20

Related Videos

video-image

Rana McKay, MD, discusses factors considered when deciding which patients to get an I-O combo in RCC

video-image

Rana McKay, MD, discusses the unmet needs for clinical trials addressing non-clear cell RCC

video-image

Rana McKay, MD, shares results of the randomized Phase 2 study investigating luPSMA vs cabazitaxel

video-image

Rana McKay, MD, dissects the pros and cons of the virtual format of ASCO20

video-image

Rana McKay, MD, elaborates on the advent of hormonal agents for patients with metastatic prostate cancer

video-image

Rana McKay MD, explains approach to treating 2nd-line RCC patients who have received I-O combination

video-image

Rana McKay, MD, discusses the design and outcomes of the Phase 3 randomized Keynote 426 study in 1st line clear cell renal cell cancer (RCC)

video-image

Rana McKay, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Robert Coleman, MD, describes experience with virtual ASCO20

video-image

Joyce Liu, MD, describes experience with virtual ASCO20

video-image

Sara Hurvitz, MD, describes the recently reported results using PARP inhibition and cisplatin

video-image

Sara Hurvitz, MD, discusses the recently announced results of Monarch E and PALLAS adjuvant trials

video-image

Sara Hurvitz, MD, shares design and outcomes of the HER2CLIMB study in advanced breast cancer

video-image

Robert Dreicer, MD, updates us on the role of cabazitaxel from the CARD study

video-image

Robert Dreicer, MD, on the utilization of PSMA PET scanning & biomarkers in prostate cancer

video-image

Robert Dreicer, MD, provides results presented concerning PSMA-linked 177Lutethium regarding mCRPC

video-image

Robert Dreicer, MD, describes the results of the Javelin-100 Bladder cancer trial

video-image

Debu Tripathy, MD, describes the evolving role of PARP inhibitors in breast cancer patients

video-image

Debu Tripathy, MD, introduces new information onCDK4/6 inhibitors discussed at ASCO20

video-image

Debu Tripathy, MD, on presentations pertaining to immunotherapy in early breast cancer treatment

video-image

Debu Tripathy, MD, discusses recent FDA approvals and HER2+ metastatic breast cancer management

video-image

Toni Choueiri, MD, describes potential importance of combining ipi/nivo for 1st line renal cell carcinoma patients

video-image

Toni Choueiri, MD, describes treatment strategies for 2nd line renal cell carcinoma

video-image

Dana Chase, MD, FACOG, shares thoughts on the role of I-O in GTT management

video-image

Dana Chase, MD, FACOG, provides thoughts on the clinical evidence of secondary cytoreductive surgery

video-image

Dana Chase, MD, FACOG, on interpretations of the overall survival results of the Phase 3 SOLO2 study

video-image

Dana Chase, MD, FACOG, summarizes the outcomes of the NRG-GY004 phase III study in ovarian cancer

video-image

Derek Raghavan, MD, examines the projected cost of new GNRH antagonist therapy and its implications

video-image

Derek Raghavan, MD, discusses the efficacy and utility of the new GNRH antagonist, Reugolix

video-image

Derek Raghavan, MD, explains toxicities and factors determining GNRH-based therapies selection

video-image

Derek Raghavan, MD, provides a general overview of prostate cancer therapies

video-image

Derek Raghavan, MD, on the role of nephrectomy in the age of targeted therapies and immunotherapy

video-image

Derek Raghavan, MD, discusses Mobile screening Chest CT project for use in underserved populations

video-image

Toni Choueiri, MD, provides observations into the dynamic field of kidney cancer

video-image

Toni Choueiri, MD, considers the next steps in the further development of HIF-2 inhibitors

video-image

Toni Choueiri, MD, makes predictions for triplet combinations in the treatment of RCC

video-image

Toni Choueiri, MD, discusses approach to first line treatment of clear cell renal cell cancers

video-image

Toni Choueiri, MD, provides updates on HIF-2 alpha inhibitors in renal call cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, describes the role of PARP inhibitors advanced prostate cancer

video-image

Nicholas Vogelzang, MD, FASCO, FACP, provides updates on PSMA radioligands for PET imaging

video-image

Nicholas Vogelzang, MD, discusses re-emergence of dose reduced cabozantinib + alezotuzumab in aPC

video-image

Nicholas Vogelzang, MD, provides thoughts on the role of radium 223 in management of aMPC

video-image

Nicholas Vogelzang, MD, explains how cabazitaxel should be used in various lines of treatment in mPC

video-image

Nicholas Vogelzang, MD, FASCO, FACP, considers the dosing effects of cabazitaxel in clinical studies

video-image

Nicholas Vogelzang, MD, FASCO, FACP, on CARD study impressions comparing novel hormonal therapy to cabazitaxel

video-image

Nicholas Vogelzang, MD, FASCO, FACP, updates us on the status of PSMA-linked radiopharmaceuticals

video-image

Marcia Brose, MD, PhD, provides opinion on who should be tested TRK fusions

video-image

Marcia Brose, MD, PhD, expounds on what should be done for patients who progress on larotrectinib

video-image

Marcia Brose, MD, PhD, on biopsy requirements for optimal evaluation for actionable TRK fusions

video-image

Marcia Brose, MD, PhD, describes how testing for TRK abnormalities are accomplished

video-image

Marcia Brose, MD, PhD, discusses the dosing, safety and efficacy of larotrectinib reported at ASCO20

video-image

Marcia Brose, MD, PhD, provides an overview of TRK fusion treatment in cancer patients

video-image

Tomasz Beer, MD, FACP, discusses the recently FDA approved relugolix

video-image

Tomasz Beer, MD, FACP, provides preliminary data presented concerning androgen receptor degraders

video-image

Tomasz Beer, MD, FACP, on how to treat patients who are progressing on androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, explains which nmCRPC patients to treat with androgen receptor inhibitors

video-image

Tomasz Beer, MD, FACP, reviews updates concerning androgen receptor inhibitors in nmCRPC

video-image

Edward Garon MD, expounds on the new FDA approval of erlotinib + ramuciramab in EGFR positive advanced non-small cell lung cancer (NSCLC)

video-image

Edward Garon, MD, examines the ADAURA clinical study regarding adjuvant treatment in NSCLC

video-image

Edward Garon, MD, examines dual immunotherapy approach in the CITYSCAPE trial

video-image

Edward Garon, MD, discusses length of use when combining I-O with chemotherapy in 1st line NSCLC

video-image

Andres Poveda, MD, provides perspective on the digital format of ASCO20

video-image

Andres Poveda, MD, considers the role of PARP inhibitors in advanced ovarian cancer

video-image

Andres Poveda, MD, discusses the BRCA mutation and homologous recombination deficiency

video-image

Andres Poveda, MD, shares design and outcomes of the PHASE 3 SOLO2 regarding ovarian cancer

video-image

Nancy Lin, MD, on impressions of the Phase 2 study the by the Translational Breast Cancer Consortium

video-image

Nancy Lin, MD, explores the role of CDK4/6 inhibitors in metastatic breast cancer management

video-image

Nancy Lin, MD, discusses the standard of care when adjuvant treating HR+, HER2- early breast cancer

video-image

Nancy Lin, MD, provides perspective on the global Phase 3 PALLAS trial regarding early breast cancer

video-image

Nancy Lin, MD, considers whether the results of the HER2CLIMB study will become a new care standard

video-image

Nancy Lin, MD, on the design and outcomes of the HER2CLIMB study regarding metastatic breast cancer

video-image

Danny Rischin, MD, considers whether Libtayo (cemiplimab) is a standard of care in advanced CSCC

video-image

Danny Rischin, MD, discusses unmet needs and how advanced CSCC was treated prior to cemiplimab

video-image

Danny Rischin, MD, shares long-term outcomes of the clinical study regarding advanced CSCC

video-image

Scott Tagawa, MD, elaborates on what may account for resistance to PSMA radioligand therapies

video-image

Scott Tagawa, MD, explains how PSMA PET imaging is utilized with PSMA-based therapies

video-image

Scott Tagawa, MD, defines the 177Lutethium Beta emitter and the 225Actinium Alpha emitter PMSA-linked therapies

video-image

Scott Tagawa, MD, considers next steps in the development of the PSMA-targeted alpha emitter in mCRPC

video-image

Scott Tagawa, MD, discusses the results of Phase I dose-escalation study regarding mCRPC

video-image

Daneng Li, MD, considers the role of cabozantinib and other TKIs as HCC patients progress on I-O

video-image

Daneng Li, MD, discusses the recent FDA approval of combining atezolizumab + bevacizumab in HCC

video-image

Daneng Li, MD, on the study results investigating the geriatric assessment tool & chemo side effects

video-image

Daneng Li, MD, describes the geriatric assessment tool developed at City of Hope

video-image

Shaji Kumar, MD, discusses excitement about bispecific antibodies in multiple myeloma

video-image

Shaji Kumar, MD, provides perspective on the role of anti-CD38 antibodies changing multiple myeloma

video-image

Shaji Kumar, MD, shares the design and outcomes of the CARTITUDE-1 trial regarding multiple myeloma

video-image

Shaji Kumar, MD, shares the take home message for physicians treating 1st line multiple myeloma

video-image

Roy Herbst, MD, PhD, discusses next steps in clinical development of osimertinib in adjuvant NSCLC

video-image

Roy Herbst, MD, PhD, explains the 3-year length of adjuvant treatment strategy in ADAURA

video-image

Roy Herbst, MD, PhD, considers assessing NSCLC patients who recur after completing adjuvant osimertinib(Tagrisso)

video-image

Xiuning Le, MD, PhD, describes experience with virtual ASCO20

video-image

Xiuning Le, MD, PhD, shares impressions of the randomized Phase 2 CITYSCAPE study regarding NSCLC

video-image

Xiuning Le, MD, PhD, describes the ADAURA clinical study as an adjuvant treatment in NSCLC

video-image

Xiuning Le, MD, PhD, considers tepotinib development going forward as a result of the VISION study

video-image

Dana Chase, MD, considers the role of PARP inhibitors in advanced ovarian cancer today

video-image

Dana Chase, MD, shares details about PRIMA and PAOLA clinical studies regarding ovarian cancer

video-image

Xiuning Le, MD, PhD, discusses testing for METex14 skipping and validating it in the VISION study

video-image

Xiuning Le, MD, PhD, discusses the mechanism of action for tepotanib and how it targets NSCLC

video-image

Bruce Feinberg, DO, elaborates on surprising findings in Oncology Insights 7th edition study

video-image

Bruce Feinberg DO, explains strategies that are or should be provided for managing cancer survivors

video-image

Bruce Feinberg, DO, provides examples of social determinants of health and how they qualify as this

video-image

Bruce Feinberg, DO, discusses the importance of social determinants to the health of cancer patient's outcomes

video-image

Joyce Liu, MD, provides perspective on the large studies in advanced ovarian cancer

video-image

Joyce Liu, MD, on overall survival outcomes of Phase 3 SOLO2 study regarding advanced ovarian cancer

video-image

Joyce Liu, MD, shares thoughts on the activity of the Wee1 inhibitor as monotherapy in USC

video-image

Joyce Liu, MD, provides good news, in spite of Phase 3 NRG-GY004 study being negative

video-image

Joyce Liu, MD, summarizes the outcomes of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Joyce Liu, MD, provides background and design of the NRG-GY004 phase III study regarding ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, describes the overall survival outcomes of the Phase 3 SOLO2 clinical study

video-image

Robert Coleman, MD, FACOG, FACS, explains the underlying biology of homologous recombination deficiency

video-image

Robert Coleman, MD, FACOG, FACS, discusses the 2 recent FDA approvals for PARP inhibitors in ovarian cancer

video-image

Robert Coleman, MD, FACOG, FACS, provides thoughts on the NRG-GY004 phase III study

video-image

Robert Coleman, MD, FACOG, FACS, shares conclusions that can be drawn from phase 3 GOG213 study at ASCO20

video-image

Salvatore Siena, MD, on his study investigating trastuzumab deruxtecan in HER2+ mCRC patients

video-image

Salvatore Siena, MD, on what is next for Enhertu (trastuzumab deruxtecan) in clinical development

video-image

Salvatore Siena, MD, discusses the incidence of HER2+ patients amongst CRC patients

video-image

Sankalp Sethi & Jeffrey Patton, MD, on how pharma can help community oncology’s COVID-19 challenges

video-image

Constantine Tam, MD, & Robert Figlin, MD, FACP, discuss progress in Waldenstrom’s Macroglobulinemia & ASCO20

video-image

Tanios Bekaii-Saab, MD, FACP, considers the emerging role of immunotherapy in advanced CRC treatment

video-image

Tanios Bekaii-Saab, MD, FACP, discusses oral chemotherapy in adjuvant and advanced CRC treatment during the COVID era

video-image

Thierry Andre, MD, on evolution of I-O towards the first line treatment of colorectal cancer

video-image

Thierry Andre, MD, provides thoughts on how to identify patients with CRC unlikely to respond to I-O

video-image

Thierry Andre, MD, shares design of the Keynote-177 study in metastatic colorectal cancer

video-image

Thierry Andre, MD, regarding the outcomes of the Keynote-177 study in metastatic colorectal cancer

video-image

Matthew Galsky, MD, discusses how to identify patients that will likely be good responders for I-O

video-image

Matthew Galsky, MD, considers a new standard of maintenance with the Javelin study outcomes

video-image

Matthew Galsky, MD, shares the design and outcomes of the Javelin Bladder 100 study

video-image

Matthew Galsky, MD, explains which biomarkers likely have the most predictive value

video-image

Matthew Galsky, MD, tells us about the Phase 3 IMvigor130 study in advanced urothelial cancer

video-image

Bruce Feinberg, DO, on the understanding medical oncologists have on social determinants of health

video-image

Shaji Kumar, MD, shares results of the Phase 3 study regarding 1st line multiple myeloma treatment

video-image

Roy Herbst, MD, PhD, shares perspective on the plenary session presentation of the ADAURA study

video-image

Xiuning Le, MD, PhD, discusses goals and results of the VISION study in non-small cell lung cancer

video-image

Jorge Cortes, MD, on the evolution of CAR-T cell therapies in hematologic malignancies management

video-image

Jorge Cortes, MD, discusses the take home message from the OPTIC study in CML patients for HCPs

video-image

Jorge Cortes, MD, provides thoughts on what the impact of the OPTIC study will be on CML patients

video-image

Jorge Cortes, MD, tells us about the OPTIC study, a phase 2 investigation of ponatinib in CML

video-image

Howard Hochster, MD, regarding abstract 4009 at ASCO20 looking at the use of ctDNA in CRC patients

video-image

Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers

video-image

Howard Hochster, MD, on whether atezolizumab + bevacizumab regimen is a new standard in care in HCC

video-image

Howard Hochster, MD, provides thoughts on the clinical progress of Enhertu in GI cancers

video-image

Howard Hochster, MD, provides thoughts on the potential practice changing results of the Keynote-177 study

video-image

Howard Hochster, MD, discusses the outcomes of the Keynote-177 study in metastatic CRC

video-image

Alan Venook, MD, provides opinions of the OPRA data in rectal cancer patients presented at ASCO20

video-image

Alan Venook, MD, on potential new standard in care post approval of atezolizumab + bevacizumab

video-image

Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers

video-image

Alan Venook, MD, considers how I-O is evolving towards the first line treatment of colorectal cancer

video-image

Alan Venook, MD, describes the potential practice changing results of the Keynote-177 study

video-image

Alan Venook, MD, on the Keynote-177 study investigating MSI High/mismatch repair deficient mCRC

video-image

Alan Venook, MD, discusses uniqueness of MSI-High/mismatch repair deficient CRC patients

video-image

Katie Kelley, MD, provides thoughts on the potential practice changing Study 22 results

video-image

Saad Usmani, MD, shares perspective on the addition of elotuzimab in multiple myeloma

video-image

Elizabeth Plimack, MD, explains how to identify patients who are good candidates for I-O in bladder cancer

video-image

Saad Usmani, MD, discusses the promise bispecific antibodies may hold in multiple myeloma management

video-image

Yuanbin Chen, MD, explains the impact of the 2nd arm in the CASPIAN study in small cell lung cancer

video-image

Katie Kelley, MD, differentiates the HIMALAYA study from Study 22 and I-O adoption in HCC treatment

video-image

Yuanbin Chen, MD, discusses the potential practice changing outcomes of the CASPIAN trial

video-image

Elizabeth Plimack, MD, on differentiating 1st line RCC patients when selecting a combination regimen

video-image

Katie Kelley, MD, explains the design of the Phase 2 Study 22 investigating tremelimumab + Imfinzi (durvalumab) in hepatocellular cancer (HCC) patients

video-image

Saad Usmani, MD, on impressions of the CARTITUDE study in relapsed/refractory multiple myeloma patients

video-image

Saad Usmani, MD, shares what impresses him about the BOSTON study in multiple myeloma patients after 1 to 3 prior therapies

video-image

Elizabeth Plimack, MD, describes her ASCO20 experience in the virtual setting

video-image

Elizabeth Plimack, MD, on treating 2nd line RCC patients that have received an I-0 combination in the 1st line setting

video-image

Charles Rudin, MD, PhD, shares the take home message regarding Keynote-604 for lung cancer treatment

video-image

Charles Rudin, MD, PhD, discusses the Keynote-604 study and the role of Keytruda in ES-SCLC

video-image

Karen Lu, MD, discusses how PARP inhibitors have changed the management of advanced ovarian cancer

video-image

Karen Lu, MD, illustrates challenges the MAGENTA study brings up associated with genetic counseling

video-image

Karen Lu, MD, provides opinion on whether genetic counseling should be part of the SOP for breast and ovarian cancer risk

video-image

Karen Lu, MD, shares outcomes of the MAGENTA study investigating the role of genetic counseling

video-image

Jesus Berdeja, MD, explains how BCMA targeting differs from other CAR-T cell therapies

video-image

Jesus Berdeja, MD, describes the evolving role of CAR-T therapies in multiple myeloma

video-image

Eric Jonasch, MD, discusses the incidence of Von Hippel-Lindau Disease among RCC patients

video-image

Eric Jonasch, MD, expounds on the use of MK-6482 in both RCC and non-RCC tumors

video-image

Eric Jonasch, MD, explains the development process for MK-6482 and hopes for future studies

video-image

Eric Jonasch, MD, on the 4 year Checkmate-214 follow up investigating nivolumab + ipilimumab

video-image

Eric Jonasch, MD, considers the combination and/or sequencing IO and TKIs in advanced RCC management

video-image

Eric Jonasch, MD, recognizes interesting clinical presentations regarding RCC management at ASCO20

video-image

Fred Saad MD, on SPARTAN study highlights for oncologists that do not specialize in prostate cancer

video-image

Fred Saad, MD, on genetic testing to be conducted in a patient with metastatic prostate cancer

video-image

Fred Saad, MD, shares impressions of the CARD study investigating cabazitaxel in nmCRPC patients

video-image

Fred Saad, MD, details safety concerns when prescribing apalutamide + ADT to nmCRPC patients

video-image

Katie Kelley, MD, discusses fitting tremelimumab + durvalumab into HCC treatment algorithms

video-image

Saad Usmani, MD, outlines the Phase 1 study investigating teclistamab in relapsed/refractory multiple myeloma

video-image

Elizabeth Plimack, MD, explains the design and outcomes of the Phase 3 randomized Keynote 426 study

video-image

Yuanbin Chen, MD, shares outcomes of the Phase 3 CASPIAN trail investigating Imfinzi (durvalumab) + chemotherapy

video-image

Vivek Subbiah, MD, on the FDA approved product, selpercatanib, for RET-driven lung and thyroid cancers

video-image

Vivek Subbiah, MD, describes solid tumor tests for RET fusion and similarities it may have to other targeted therapy tests

video-image

Charles Rudin, MD, PhD, shares outcomes of the Keynote 604 study investigating the combination of Keytruda and chemotherapy in ES-small cell lung cancer patients

video-image

Vivek Subbiah, MD, on developing targeted therapies for RET fusion + solid tumors and the effectivity

video-image

Vivek Subbiah, MD, describes the incidence of RET fusion + solid tumors amongst cancer patients and when RET-fusion + targeted therapies will be most effective

video-image

Karen Lu MD, elaborates on the underlying biology of homologous recombination deficiency (HRD) and how it applies to ovarian cancer management

video-image

Jesus Berdeja, MD, shares the design and outcomes of the CARTITUDE-1 trial investigating the BCMA-targeted CAR-T cell therapy JNJ-4528 in relapsed/refractory multiple myeloma patients

video-image

Eric Jonasch, MD, explains MK-6482 and the tumor types it will be most effective in

video-image

Fred Saad, MD, shares the design and outcomes of the SPARTAN study in patients with nmCRPC

video-image

Véronique Diéras, MD, on the optimal setting in which to receive a PARP inhibitor

video-image

Véronique Diéras, MD, on BRCA-positive metastatic breast cancer & PARP inhibitors

video-image

George Sledge, MD, shares the most relevant findings from the MONARCH-2 trial

video-image

Dennis J. Slamon, MD, PhD, on the significance of the phase III MONALEESA-3 trial

video-image

Véronique Diéras, MD, elaborates on the BROCADE 3 study presented at ESMO 2019

video-image

Banu Arun, MD, regarding the optimal setting for PARP inhibitors in breast cancer treatment

video-image

Banu Arun, MD, on PARP inhibitors in BRCA positive metastatic breast cancer

video-image

Banu Arun, MD, regarding veliparib in breast cancer patients with BRCA mutations

video-image

Joyce O’Shaughnessy, MD, elaborates on the MONALEESA-3 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, shares relevant findings from the MONARCH-2 trial

video-image

Joyce O’Shaughnessy, MD, on the role of CDK4/6 inhibitors in the management of TNBC

video-image

Joyce O’Shaughnessy, MD, shares results of the Impassion130 trial presented at ESMO 2019

video-image

Joyce O’Shaughnessy, MD, on differentiating CDK4/6 inhibitors